申请人:Persons E. Paul
公开号:US20070093522A1
公开(公告)日:2007-04-26
One aspect of the present invention relates to novel peptidomometic compounds. A second aspect of the present invention relates to the use of the novel peptidomimetic compounds as ligands—agonists or antagonists—for various cellular receptors, e.g., G-protein-coupled receptors and opioid receptors, and various cellular ion channels, e.g., sodium and calcium. In certain embodiments, compounds of the present invention preferentially or selectively inhibit sodium or calcium ion channels. In certain embodiments, compounds of the present invention preferentially or selectively agonize or antagonize μ opioid receptors. In certain embodiments, compounds of the present invention preferentially or selectively inhibit sodium or calcium ion channels and agonize or antagonize μ-opioid receptors.
本发明的一个方面涉及新型肽类模拟化合物。本发明的第二个方面涉及将新型肽类模拟化合物用作各种细胞受体的配体-激动剂或拮抗剂,例如G蛋白偶联受体和阿片受体,以及各种细胞离子通道,例如钠和钙。在某些实施方式中,本发明的化合物优选或选择性地抑制钠或钙离子通道。在某些实施方式中,本发明的化合物优选或选择性地激动或拮抗μ阿片受体。在某些实施方式中,本发明的化合物优选或选择性地抑制钠或钙离子通道,并激动或拮抗μ阿片受体。